Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 4/20 | 0.31 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.30 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.30 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277076 | 0.88 | CYP3A4 (0.53) | CYP3A4HTTODC1TLR2 | |
| SCHEMBL13193551 | 0.86 | — | — | |
| SCHEMBL17126850 | 0.83 | USP2 (0.43) | CYP3A4HTTHSD17B10SPHK1USP2 | |
| SCHEMBL29330302 | 0.82 | CYP3A4 (0.37) | CYP3A4HTTHSD17B10 | |
| Dimethylamine SCHEMBL8733503 | 0.82 | CYP3A4 (0.46) | CYP3A4HTTODC1TLR2 | |
| SCHEMBL12587449 | 0.81 | CYP3A4 (0.44) | CYP3A4HTTHSD17B10SPHK1USP2 | |
| SCHEMBL2625072 | 0.81 | CYP3A4 (0.44) | CYP3A4HTTHSD17B10SPHK1USP2 | |
| SCHEMBL14952421 | 0.81 | CYP3A4 (0.44) | CYP3A4HTTHSD17B10SPHK1USP2 | |
| SCHEMBL29213133 | 0.80 | CYP3A4 (0.48) | CYP3A4ODC1 | |
| SCHEMBL13225083 | 0.80 | ADRB2 (0.42) | CYP3A4HTTODC1HSD17B10SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209589-A1 | NOVEL CONJUGATION REAGENTS | ABZENA (CAMBRIDGE) LIMITED (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9650331-B2 | Conjugation reagents | POLYTHERICS LIMITED (GB) | 2017-05-16 | — | — | US | disclosed |
| US-8034981-B2 | Modified bio-related substance, process for producing the same, and intermediate | NOF CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110082277-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | NOF CORPORATION (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209589-A1 | NOVEL CONJUGATION REAGENTS | QPCTL, QPCT, LANCL1 | CYP3A4 3007/4885HTT 3320/4885ODC1 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.